As of 2025-05-03, the Intrinsic Value of Biogen Inc (BIIB) is 201.67 USD. This Biogen valuation is based on the model Discounted Cash Flows (Growth Exit 5Y). With the current market price of 123.53 USD, the upside of Biogen Inc is 63.30%.
The range of the Intrinsic Value is 158.09 - 275.84 USD
Based on its market price of 123.53 USD and our intrinsic valuation, Biogen Inc (BIIB) is undervalued by 63.30%.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | 158.09 - 275.84 | 201.67 | 63.3% |
| DCF (Growth 10y) | 173.13 - 292.19 | 217.46 | 76.0% |
| DCF (EBITDA 5y) | 230.74 - 288.95 | 264.35 | 114.0% |
| DCF (EBITDA 10y) | 226.72 - 303.21 | 266.58 | 115.8% |
| Fair Value | 55.76 - 55.76 | 55.76 | -54.86% |
| P/E | 139.39 - 289.26 | 215.89 | 74.8% |
| EV/EBITDA | 278.63 - 320.08 | 297.24 | 140.6% |
| EPV | 169.76 - 247.08 | 208.42 | 68.7% |
| DDM - Stable | 73.26 - 160.76 | 117.01 | -5.3% |
| DDM - Multi | 78.72 - 143.10 | 102.39 | -17.1% |
| Market Cap (mil) | 18,100.85 |
| Beta | 0.39 |
| Outstanding shares (mil) | 146.53 |
| Enterprise Value (mil) | 22,021.70 |
| Market risk premium | 4.60% |
| Cost of Equity | 9.51% |
| Cost of Debt | 4.28% |
| WACC | 8.00% |